We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Shot in the arm

8 February 2011 By Chris Hughes

The Swiss pharma group faces bold calls from UK hedge fund Elliott Advisors to reform its board and explore a sale. Elliott’s tactics may be questionable, but its demands are reasonable. The question is how Actelion can use the situation to get an auction going.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)